Hospital
T J Samson Community Hospital
T J Samson Community Hospital was paid $95.74M by Medicaid between Jan 2018 and Dec 2024, across 525 billing codes. Its largest line is G0463, Hospital outpatient clinic visit for assessment and management of a patient — 13% of everything it billed.
33Billing provider infoT J SAMSON COMMUNITY HOSPITAL
GLASGOW, KY 42141
GLASGOW, KY 42141
33aNPI1770581894assigned 07/12/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$95.74M
24GClaims2,471,139
24DCodes billed525
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Kentucky
Rank by total paid#6 of 36
Median peer was paid$36.08M
This provider vs. median2.7×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official THORNBURY, NEIL controls 17+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 339,159 | $13.73M | |
| 2019 | 347,503 | $14.28M | |
| 2020 | 305,917 | $11.17M | |
| 2021 | 365,638 | $13.43M | |
| 2022 | 379,030 | $13.94M | |
| 2023 | 411,697 | $15.98M | |
| 2024incomplete | 322,195 | $13.22M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 13% | 187,209 | 125,108 | $12.24M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 7.3% | 32,429 | 26,000 | $7.00M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 5.1% | 18,771 | 11,083 | $4.86M |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 3.6% | 85,564 | 70,666 | $3.49M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 3.5% | 24,455 | 21,301 | $3.37M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.9% | 7,872 | 5,689 | $2.77M |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 2.5% | 45,793 | 40,579 | $2.36M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.4% | 24,775 | 17,503 | $2.27M |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | 2.2% | 8,478 | 3,232 | $2.14M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 2.2% | 46,149 | 41,682 | $2.08M |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 2.0% | 8,588 | 6,834 | $1.94M |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 2.0% | 47,487 | 40,389 | $1.93M |
513 more codes
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 1.8% | 36,490 | $1.73M |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 1.6% | 34,994 | $1.54M |
| G0379 | Direct admission of patient for hospital observation care | 1.6% | 2,582 | $1.53M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.6% | 4,546 | $1.51M |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 1.4% | 27,606 | $1.32M |
| 70450 | Computed tomography, head or brain; without contrast material | 1.3% | 8,819 | $1.22M |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 1.1% | 4,438 | $1.06M |
| G0378 | Hospital observation service, per hour | 1.1% | 8,610 | $1.03M |
| 47562 | 1.1% | 550 | $1.02M | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.0% | 47,699 | $995K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 23,512 | $939K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 26,239 | $923K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 20,826 | $920K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 1,829 | $896K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 2,006 | $878K |
| 80053 | Comprehensive metabolic panel | <1% | 85,400 | $857K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 12,923 | $839K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 39,918 | $808K |
| 36415 | Collection of venous blood by venipuncture | <1% | 210,093 | $801K |
| 76830 | Ultrasound, transvaginal | <1% | 6,600 | $759K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 38,733 | $676K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 2,131 | $644K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 8,261 | $642K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 671 | $640K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 12,048 | $593K |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 256 | $584K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 1,153 | $577K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 12,391 | $549K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 89,724 | $531K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 8,591 | $525K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 2,666 | $464K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 14,823 | $450K |
| 71045 | Radiologic examination, chest; single view | <1% | 17,057 | $441K |
| 97597 | <1% | 7,258 | $391K | |
| 95811 | <1% | 837 | $388K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 3,717 | $386K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 4,208 | $365K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 28,715 | $360K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 2,163 | $355K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 5,033 | $346K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 3,995 | $329K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 6,903 | $321K |
| 72141 | <1% | 976 | $311K | |
| 94060 | <1% | 3,803 | $307K | |
| 93017 | <1% | 3,286 | $304K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 4,620 | $304K |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 2,075 | $301K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 1,055 | $290K |
| 97113 | <1% | 3,954 | $288K | |
| J3490 | Unclassified drugs | <1% | 35,178 | $282K |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 7,512 | $278K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 45,352 | $276K |
| 80061 | Lipid panel | <1% | 25,445 | $263K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,778 | $262K |
| 80081 | <1% | 3,736 | $262K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 34,202 | $240K |
| 76801 | <1% | 3,371 | $234K | |
| 96367 | <1% | 3,771 | $228K | |
| G0399 | Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | <1% | 2,329 | $210K |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 833 | $195K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 920 | $190K |
| 71250 | <1% | 1,659 | $188K | |
| 74018 | <1% | 5,701 | $183K | |
| 76770 | <1% | 1,765 | $175K | |
| J7307 | Etonogestrel (contraceptive) implant system, including implant and supplies | <1% | 244 | $172K |
| 78227 | <1% | 575 | $169K | |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | <1% | 1,746 | $163K |
| 93971 | <1% | 1,669 | $156K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 9,845 | $151K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 308 | $149K |
| 92526 | <1% | 2,808 | $142K | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 2,582 | $142K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 4,031 | $141K |
| 74022 | <1% | 2,527 | $138K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 1,112 | $136K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 428 | $133K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 1,304 | $132K |
| 82607 | <1% | 11,413 | $128K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 6,859 | $126K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 19,734 | $125K |
| 87428 | <1% | 3,749 | $124K | |
| 72100 | <1% | 3,301 | $124K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 229 | $122K |
| 97161 | <1% | 3,292 | $121K | |
| 80306 | <1% | 11,929 | $120K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 4,785 | $120K |
| 81001 | <1% | 49,674 | $119K | |
| 73630 | <1% | 4,411 | $119K | |
| 97162 | <1% | 3,000 | $118K | |
| 92523 | <1% | 978 | $117K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 5,860 | $115K |
| 87150 | <1% | 3,865 | $115K | |
| 87641 | <1% | 5,574 | $113K | |
| 90715 | <1% | 3,482 | $112K | |
| 43235 | <1% | 211 | $112K | |
| 84484 | <1% | 17,349 | $112K | |
| 73610 | <1% | 3,979 | $110K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 4,750 | $108K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 3,538 | $106K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 6,049 | $105K |
| 74019 | <1% | 2,936 | $104K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 21,086 | $103K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 3,514 | $103K |
| 73030 | <1% | 3,823 | $102K | |
| 73130 | <1% | 3,611 | $101K | |
| 87486 | <1% | 4,559 | $101K | |
| 87581 | <1% | 4,435 | $99K | |
| 83880 | <1% | 6,180 | $94K | |
| 20610 | <1% | 1,040 | $93K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 2,121 | $91K |
| 94726 | <1% | 1,792 | $90K | |
| 76536 | <1% | 917 | $88K | |
| 73110 | <1% | 2,952 | $87K | |
| 93454 | <1% | 219 | $87K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 2,182 | $87K |
| 73562 | <1% | 3,193 | $86K | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 2,097 | $84K |
| 84702 | <1% | 8,075 | $83K | |
| 70544 | <1% | 390 | $81K | |
| 87070 | <1% | 11,297 | $81K | |
| 88304 | <1% | 2,955 | $80K | |
| 84439 | <1% | 11,189 | $77K | |
| 76642 | <1% | 1,375 | $76K | |
| 72110 | <1% | 1,319 | $73K | |
| 85027 | <1% | 16,779 | $67K | |
| 86900 | <1% | 5,301 | $67K | |
| 81025 | <1% | 14,626 | $65K | |
| J2704 | Injection, propofol, 10 mg | <1% | 12,380 | $64K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 9,985 | $60K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 18,155 | $59K |
| 73502 | <1% | 1,932 | $59K | |
| 82565 | <1% | 7,674 | $58K | |
| 82728 | <1% | 5,469 | $58K | |
| 84403 | <1% | 2,695 | $57K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 547 | $55K |
| 71271 | <1% | 1,253 | $54K | |
| 96376 | <1% | 3,635 | $54K | |
| 83690 | <1% | 12,558 | $52K | |
| 95117 | <1% | 4,071 | $52K | |
| 87186 | <1% | 8,926 | $52K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 805 | $52K |
| 72072 | <1% | 1,184 | $51K | |
| 97750 | <1% | 2,007 | $50K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 11,356 | $50K |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 2,162 | $49K |
| 76818 | <1% | 803 | $49K | |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 50 | $49K |
| 80074 | <1% | 1,476 | $48K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 1,117 | $48K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 99 | $47K |
| 58563 | <1% | 32 | $46K | |
| 80051 | <1% | 8,900 | $46K | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 4,120 | $45K |
| 70486 | <1% | 261 | $43K | |
| 0225U | <1% | 129 | $43K | |
| 83735 | <1% | 10,304 | $43K | |
| C1769 | Guide wire | <1% | 1,970 | $42K |
| 86803 | <1% | 4,112 | $42K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 2,321 | $41K |
| 72040 | <1% | 1,235 | $38K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 3,495 | $38K |
| 88312 | <1% | 1,396 | $38K | |
| 85610 | <1% | 13,796 | $37K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 3,721 | $36K |
| 62323 | <1% | 171 | $36K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 22,989 | $35K |
| 87040 | <1% | 6,585 | $35K | |
| 83001 | <1% | 2,154 | $35K | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 200 | $34K |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 2,154 | $34K |
| 85730 | <1% | 9,694 | $33K | |
| 73080 | <1% | 1,239 | $33K | |
| 77066 | Tomosynthesis, mammo | <1% | 398 | $32K |
| 87077 | <1% | 4,797 | $31K | |
| 64493 | <1% | 107 | $31K | |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 489 | $31K |
| 94729 | <1% | 1,862 | $31K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 5,960 | $31K |
| 87088 | <1% | 5,722 | $31K | |
| 72050 | <1% | 494 | $31K | |
| 73560 | <1% | 992 | $30K | |
| 83002 | <1% | 1,926 | $30K | |
| 12001 | <1% | 605 | $30K | |
| G0008 | Administration of influenza virus vaccine | <1% | 1,066 | $30K |
| 36600 | <1% | 1,788 | $30K | |
| J1815 | Injection, insulin, per 5 units | <1% | 2,053 | $30K |
| 83540 | <1% | 6,685 | $29K | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 1,586 | $28K |
| 84481 | <1% | 2,092 | $28K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 92 | $28K |
| 82670 | <1% | 1,082 | $28K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 7,854 | $27K |
| 83550 | <1% | 4,692 | $27K | |
| 82746 | <1% | 2,627 | $27K | |
| 84703 | <1% | 4,144 | $27K | |
| 84146 | <1% | 1,569 | $26K | |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 112 | $26K |
| 99153 | Mod sedat endo service >5yrs | <1% | 873 | $26K |
| 73090 | <1% | 965 | $25K | |
| 73221 | <1% | 99 | $25K | |
| 99152 | <1% | 1,452 | $25K | |
| 87075 | <1% | 4,110 | $25K | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 215 | $24K |
| J7999 | Compounded drug, not otherwise classified | <1% | 2,803 | $24K |
| 73590 | <1% | 844 | $24K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 8,712 | $24K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 9,628 | $24K |
| 82962 | <1% | 5,460 | $23K | |
| 86850 | <1% | 3,208 | $21K | |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 94 | $21K |
| 82803 | <1% | 1,969 | $20K | |
| J2790 | Injection, rho d immune globulin, human, full dose, 300 micrograms (1500 i.u.) | <1% | 244 | $20K |
| 80076 | <1% | 3,239 | $20K | |
| 82947 | <1% | 6,034 | $20K | |
| 70491 | <1% | 91 | $19K | |
| 82950 | <1% | 3,570 | $19K | |
| 93458 | <1% | 135 | $19K | |
| J2805 | Injection, sincalide, 5 micrograms | <1% | 227 | $18K |
| 86038 | <1% | 1,966 | $18K | |
| 80069 | <1% | 2,994 | $18K | |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 52 | $18K |
| 90686 | <1% | 2,627 | $18K | |
| 90677 | <1% | 622 | $18K | |
| 99406 | <1% | 1,308 | $18K | |
| 83605 | <1% | 3,272 | $17K | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 1,364 | $16K |
| 80050 | General health panel | <1% | 1,087 | $16K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,941 | $16K |
| J7298 | Levonorgestrel-releasing intrauterine contraceptive system (mirena), 52 mg | <1% | 26 | $16K |
| 81003 | <1% | 6,725 | $16K | |
| 0012A | <1% | 930 | $16K | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 829 | $16K |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | <1% | 69 | $15K |
| 86140 | <1% | 3,955 | $15K | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 772 | $15K |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 585 | $15K |
| 96161 | <1% | 1,022 | $15K | |
| 97166 | <1% | 255 | $15K | |
| 82150 | <1% | 3,850 | $15K | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 1,829 | $15K |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 250 | $14K |
| 86376 | <1% | 1,357 | $14K | |
| 0011A | <1% | 1,003 | $14K | |
| 84144 | <1% | 909 | $14K | |
| 85007 | <1% | 5,662 | $14K | |
| 95816 | <1% | 113 | $14K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 4,341 | $14K |
| 10060 | <1% | 117 | $13K | |
| 72131 | <1% | 110 | $13K | |
| 97165 | <1% | 448 | $13K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 8,112 | $13K |
| J0585 | Injection, onabotulinumtoxina, 1 unit | <1% | 24 | $13K |
| C1889 | Implantable/insertable device, not otherwise classified | <1% | 445 | $13K |
| 82043 | <1% | 3,234 | $13K | |
| 87522 | Neg quan hep c or qual rna | <1% | 443 | $12K |
| 82570 | <1% | 3,270 | $12K | |
| 86308 | <1% | 2,892 | $12K | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 1,814 | $12K |
| 95819 | <1% | 79 | $12K | |
| 84402 | <1% | 572 | $12K | |
| 86901 | <1% | 3,994 | $11K | |
| 17110 | <1% | 106 | $11K | |
| 99495 | <1% | 323 | $11K | |
| 84550 | <1% | 2,870 | $11K | |
| 87205 | <1% | 4,346 | $11K | |
| 84145 | <1% | 945 | $11K | |
| 71101 | <1% | 335 | $10K | |
| 76641 | <1% | 105 | $10K | |
| 59025 | Fetal non-stress test | <1% | 104 | $10K |
| C1886 | Catheter, extravascular tissue ablation, any modality (insertable) | <1% | 51 | $10K |
| 86592 | <1% | 2,567 | $10K | |
| 82375 | <1% | 1,533 | $10K | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 995 | $10K |
| 83525 | <1% | 1,025 | $9K | |
| G0297 | Low dose ct scan (ldct) for lung cancer screening | <1% | 226 | $9K |
| 87350 | <1% | 1,079 | $9K | |
| 93270 | <1% | 326 | $9K | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 132 | $9K |
| 84520 | <1% | 4,417 | $9K | |
| 85652 | <1% | 4,534 | $9K | |
| 84112 | <1% | 168 | $9K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 352 | $9K |
| 85379 | <1% | 1,601 | $9K | |
| Q9950 | Injection, sulfur hexafluoride lipid microspheres, per ml | <1% | 106 | $8K |
| G0009 | Administration of pneumococcal vaccine | <1% | 244 | $8K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 192 | $8K |
| 82550 | <1% | 1,988 | $8K | |
| 87046 | <1% | 562 | $8K | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 3,388 | $8K |
| 80143 | <1% | 804 | $7K | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 1,931 | $7K |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 1,211 | $7K |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 1,305 | $7K |
| 96523 | <1% | 453 | $7K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 10,321 | $7K |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 742 | $7K |
| 86800 | <1% | 633 | $7K | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 653 | $7K |
| 77065 | Tomosynthesis, mammo | <1% | 99 | $7K |
| 87634 | <1% | 173 | $7K | |
| 80179 | <1% | 689 | $6K | |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | <1% | 197 | $6K |
| 87081 | <1% | 280 | $6K | |
| 58100 | <1% | 60 | $6K | |
| 83516 | <1% | 376 | $6K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 187 | $6K |
| 76870 | <1% | 88 | $6K | |
| 97802 | <1% | 151 | $6K | |
| 29075 | <1% | 40 | $6K | |
| 86430 | <1% | 1,264 | $6K | |
| 84436 | <1% | 1,136 | $6K | |
| 90670 | <1% | 734 | $5K | |
| 85018 | <1% | 1,003 | $5K | |
| 87493 | <1% | 218 | $5K | |
| 72170 | <1% | 192 | $5K | |
| A9537 | Technetium tc-99m mebrofenin, diagnostic, per study dose, up to 15 millicuries | <1% | 436 | $5K |
| 85014 | <1% | 2,802 | $5K | |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 453 | $5K |
| 99499 | <1% | 85 | $5K | |
| 87045 | <1% | 679 | $5K | |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 646 | $5K |
| 97010 | <1% | 1,687 | $5K | |
| 93242 | <1% | 259 | $5K | |
| 83655 | <1% | 514 | $5K | |
| 94664 | <1% | 186 | $5K | |
| 93225 | <1% | 86 | $5K | |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 790 | $4K |
| 83615 | <1% | 965 | $4K | |
| 87340 | <1% | 664 | $4K | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 444 | $4K |
| 92583 | <1% | 137 | $4K | |
| 82627 | <1% | 202 | $4K | |
| 90651 | <1% | 71 | $4K | |
| 11102 | <1% | 43 | $4K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 3,103 | $4K |
| 82247 | <1% | 859 | $4K | |
| 86003 | <1% | 71 | $3K | |
| 82784 | <1% | 398 | $3K | |
| 58300 | <1% | 230 | $3K | |
| 86665 | <1% | 199 | $3K | |
| 11981 | <1% | 39 | $3K | |
| 73564 | <1% | 95 | $3K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 606 | $3K |
| 0064A | <1% | 375 | $3K | |
| 86885 | <1% | 414 | $3K | |
| C1773 | Retrieval device, insertable (used to retrieve fractured medical devices) | <1% | 293 | $3K |
| 73620 | <1% | 92 | $3K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 221 | $3K |
| 82951 | <1% | 249 | $3K | |
| 64615 | <1% | 31 | $3K | |
| 76882 | <1% | 79 | $3K | |
| 51798 | <1% | 219 | $3K | |
| 86480 | <1% | 63 | $3K | |
| 11982 | <1% | 14 | $3K | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 1,092 | $3K |
| 86618 | <1% | 234 | $2K | |
| 96127 | <1% | 324 | $2K | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 416 | $2K |
| 86696 | <1% | 137 | $2K | |
| 77080 | <1% | 97 | $2K | |
| 93880 | <1% | 15 | $2K | |
| 86200 | <1% | 226 | $2K | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 1,505 | $2K |
| J2060 | Injection, lorazepam, 2 mg | <1% | 970 | $2K |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 581 | $2K |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 203 | $2K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 25 | $2K |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 80 | $2K |
| 20553 | <1% | 20 | $2K | |
| 86695 | <1% | 132 | $2K | |
| 93970 | <1% | 19 | $2K | |
| 90697 | <1% | 755 | $2K | |
| 73700 | <1% | 15 | $2K | |
| A4624 | Tracheal suction catheter, any type other than closed system, each | <1% | 352 | $2K |
| 86762 | <1% | 200 | $2K | |
| 93246 | <1% | 87 | $2K | |
| 84100 | <1% | 454 | $1K | |
| Q9965 | Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml | <1% | 126 | $1K |
| 25600 | <1% | 14 | $1K | |
| 87807 | <1% | 206 | $1K | |
| A9270 | Non-covered item or service | <1% | 15,025 | $1K |
| 86664 | <1% | 110 | $1K | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 145 | $1K |
| 17000 | <1% | 32 | $1K | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 610 | $1K |
| 73521 | <1% | 14 | $1K | |
| 94618 | <1% | 38 | $1K | |
| 97167 | <1% | 15 | $1K | |
| 12011 | <1% | 25 | $1K | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 407 | $1K |
| 72082 | <1% | 18 | $1K | |
| 29105 | <1% | 15 | $1K | |
| 87210 | <1% | 192 | $1K | |
| A9698 | Non-radioactive contrast imaging material, not otherwise classified, per study | <1% | 135 | $1K |
| 77062 | <1% | 56 | $1K | |
| 51701 | <1% | 29 | $1K | |
| J2305 | Injection, nitroglycerin, 5 mg | <1% | 195 | $1K |
| 86580 | <1% | 111 | $985.33 | |
| 90656 | <1% | 249 | $893.18 | |
| 86593 | <1% | 216 | $891.03 | |
| 17250 | <1% | 17 | $885.13 | |
| 84156 | <1% | 342 | $877.44 | |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | <1% | 25 | $867.63 |
| 88307 | <1% | 19 | $854.42 | |
| 86920 | <1% | 17 | $842.73 | |
| 92610 | <1% | 16 | $832.60 | |
| 0001A | <1% | 37 | $788.08 | |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | <1% | 17 | $775.13 |
| 96160 | <1% | 67 | $767.60 | |
| 82952 | <1% | 220 | $741.07 | |
| 29125 | <1% | 27 | $738.80 | |
| 82977 | <1% | 159 | $701.07 | |
| 87209 | <1% | 47 | $686.94 | |
| 86255 | <1% | 78 | $664.61 | |
| 83013 | <1% | 16 | $663.47 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 238 | $660.69 |
| 83970 | <1% | 32 | $654.64 | |
| 84165 | <1% | 94 | $643.58 | |
| 97150 | Therapeutic procedure(s), group (2 or more individuals) | <1% | 79 | $613.22 |
| 83921 | <1% | 47 | $594.88 | |
| 84460 | <1% | 158 | $577.94 | |
| 84207 | <1% | 40 | $569.44 | |
| 82140 | <1% | 29 | $535.28 | |
| 0002A | <1% | 22 | $534.40 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 16 | $524.94 |
| 86702 | <1% | 62 | $513.92 | |
| 86704 | <1% | 59 | $505.09 | |
| 73600 | <1% | 14 | $503.19 | |
| 84132 | <1% | 190 | $480.67 | |
| 82677 | <1% | 27 | $469.45 | |
| 86706 | <1% | 61 | $464.30 | |
| 73552 | <1% | 14 | $445.38 | |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 515 | $441.50 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 85 | $432.99 |
| 90619 | <1% | 53 | $432.70 | |
| Q9956 | Injection, octafluoropropane microspheres, per ml | <1% | 16 | $423.30 |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 117 | $422.86 |
| 73120 | <1% | 15 | $418.31 | |
| 82679 | <1% | 25 | $414.43 | |
| 69210 | <1% | 13 | $403.00 | |
| 92504 | <1% | 54 | $399.18 | |
| 88302 | <1% | 54 | $396.02 | |
| 95115 | <1% | 28 | $383.65 | |
| 86701 | <1% | 63 | $382.69 | |
| 87177 | <1% | 47 | $342.38 | |
| 98929 | <1% | 44 | $342.19 | |
| 84446 | <1% | 41 | $336.97 | |
| 64494 | <1% | 42 | $329.91 | |
| 97810 | <1% | 28 | $329.03 | |
| A6449 | Light compression bandage, elastic, knitted/woven, width greater than or equal to three inches and less than five inches, per yard | <1% | 221 | $316.02 |
| 86060 | <1% | 40 | $308.51 | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 142 | $296.35 |
| A6197 | Alginate or other fiber gelling dressing, wound cover, sterile, pad size more than 16 sq. in. but less than or equal to 48 sq. in., each dressing | <1% | 127 | $284.93 |
| 88300 | <1% | 43 | $280.19 | |
| A6250 | Skin sealants, protectants, moisturizers, ointments, any type, any size | <1% | 48 | $271.69 |
| 90723 | <1% | 178 | $267.25 | |
| 90716 | <1% | 75 | $256.55 | |
| 87425 | <1% | 27 | $244.72 | |
| J0736 | Injection, clindamycin phosphate, 300 mg | <1% | 32 | $239.87 |
| C1729 | Catheter, drainage | <1% | 34 | $230.37 |
| 85246 | <1% | 12 | $229.40 | |
| 84425 | <1% | 15 | $228.43 | |
| G8987 | Self care functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 39 | $215.15 |
| 82105 | <1% | 12 | $207.80 | |
| 97035 | <1% | 26 | $201.30 | |
| J1956 | Injection, levofloxacin, 250 mg | <1% | 20 | $192.03 |
| 84153 | <1% | 12 | $190.66 | |
| 90662 | <1% | 111 | $187.43 | |
| 84155 | <1% | 73 | $163.07 | |
| 86225 | <1% | 12 | $158.80 | |
| 90474 | <1% | 14 | $144.72 | |
| Q9963 | High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml | <1% | 21 | $138.23 |
| 90833 | Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) | <1% | 15 | $138.14 |
| 86334 | <1% | 13 | $127.99 | |
| G8984 | Carrying, moving & handling objects functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 30 | $126.14 |
| 89055 | <1% | 41 | $120.09 | |
| J2471 | Injection, pantoprazole (hikma), not therapeutically equivalent to j2470, 40 mg | <1% | 90 | $112.68 |
| 82270 | <1% | 42 | $110.21 | |
| J1094 | Injection, dexamethasone acetate, 1 mg | <1% | 42 | $109.12 |
| 86008 | <1% | 12 | $107.58 | |
| 82785 | <1% | 14 | $100.15 | |
| J0595 | Injection, butorphanol tartrate, 1 mg | <1% | 35 | $98.64 |
| 85045 | <1% | 34 | $94.35 | |
| 82009 | <1% | 45 | $90.02 | |
| 87106 | <1% | 15 | $87.58 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 345 | $83.67 |
| 83090 | <1% | 12 | $71.68 | |
| 97811 | <1% | 23 | $62.64 | |
| 90633 | <1% | 420 | $60.45 | |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 15 | $43.03 |
| 81050 | <1% | 14 | $42.45 | |
| 84134 | <1% | 14 | $39.81 | |
| A4351 | Intermittent urinary catheter; straight tip, with or without coating (teflon, silicone, or silicone elastomer, etc.), each | <1% | 112 | $37.70 |
| 84450 | <1% | 16 | $30.46 | |
| Q0244 | Injection, casirivimab and imdevimab, 1200 mg | <1% | 22 | $22.23 |
| 85347 | <1% | 19 | $17.12 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 40 | $7.88 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 44 | $6.42 |
| J8597 | Antiemetic drug, oral, not otherwise specified | <1% | 51 | $5.26 |
| 90681 | <1% | 551 | $2.01 | |
| 90647 | <1% | 206 | $0.79 | |
| 90700 | <1% | 78 | $0.75 | |
| 90707 | <1% | 88 | $0.72 | |
| Q0245 | Injection, bamlanivimab and etesevimab, 2100 mg | <1% | 13 | $0.18 |
| 90671 | <1% | 27 | $0.16 | |
| 90381 | <1% | 13 | $0.02 | |
| 3078F | <1% | 660 | $0.01 | |
| G8985 | Carrying, moving and handling objects, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 14 | $0.00 |
| G9163 | Spoken language expression functional limitation, projected goal status at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 43 | $0.00 |
| 1126F | 0% | 188 | $0.00 | |
| G8988 | Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 16 | $0.00 |
| G9162 | Spoken language expression functional limitation, current status at therapy episode outset and at reporting intervals | 0% | 56 | $0.00 |
| 1125F | 0% | 60 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialTHORNBURY, NEIL (CEO)
Parent organizationT J REGIONAL HEALTH, INC.
| Provider | Location | Paid |
|---|---|---|
| T J Samson Community Hospital | Glasgow, KY | $15.53M |
| T J Health Columbia INC | Columbia, KY | $11.51M |
| T J Health Columbia INC | Columbia, KY | $1.40M |
| T J Samson Community Hospital | Glasgow, KY | $1.22M |
| T J Health Columbia INC | Edmonton, KY | $1.20M |
| T J Health Columbia INC | Columbia, KY | $682K |
| T J Health Columbia INC | Russell Springs, KY | $630K |
| T J Health Columbia INC | Scottsville, KY | $611K |
| T J Samson Community Hospital | Cave City, KY | $567K |
| T J Samson Community Hospital | Glasgow, KY | $549K |
| T J Samson Community Hospital | Glasgow, KY | $524K |
| T J Health Columbia INC | Tompkinsville, KY | $312K |
| T J Health Columbia INC | Greensburg, KY | $277K |
| T J Health Columbia INC | Columbia, KY | $125K |
| T J Samson Community Hospital | Glasgow, KY | $36K |
| T J Samson Community Hospital | Glasgow, KY | $1K |
| T J Samson Community Hospital | Glasgow, KY | $0.00 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.